For the quarter ending 2026-03-31, AZTA had -$102,698K decrease in cash & cash equivalents over the period. $6,110K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -160,798 | -15,432 | 50,839 | -106,602 |
| Depreciation and amortization | 14,002 | 13,648 | 14,434 | 46,775 |
| Impairment of goodwill and intangible assets | 149,083 | - | 0 | 0 |
| Non-cash gain from settlement of preexisting contractual relationship | 3,858 | - | - | - |
| Loss on assets held for sale | 6,269 | 9,696 | 93 | 93,025 |
| Property, plant and equipment and other asset write-offs | - | - | 3,478 | - |
| Inventory write-downs | - | - | 0 | - |
| Other non-cash charges related to restructuring and transformation | - | - | 0 | - |
| Inventory write-downs and other asset write-offs | 2,188 | -4,171 | - | 3,866 |
| Stock-based compensation | 6,362 | 4,058 | 4,994 | 15,887 |
| Contingent consideration adjustment | - | - | 0 | - |
| Amortization and accretion on marketable securities | 308 | 374 | 260 | 1,318 |
| Deferred income taxes | 490 | -5,788 | -7,013 | -20,025 |
| Purchase accounting impact on inventory | - | - | 0 | - |
| Loss (gain) on disposals of property, plant and equipment | -61 | 42 | 48 | -759 |
| Accounts receivable | -7,818 | -723 | 17,760 | -38,799 |
| Inventories | -3,029 | 9,729 | -7,398 | 10,069 |
| Accounts payable | -8,952 | 4,572 | 1,739 | -702 |
| Deferred revenue | 3,946 | 3,195 | -6,515 | 7,156 |
| Accrued warranty and retrofit costs | 126 | -248 | -471 | 36 |
| Accrued compensation and tax withholdings | -1,087 | -5,158 | 4,417 | 3,010 |
| Long term income taxes receivable | - | - | 45,600 | - |
| Accrued restructuring costs | 257 | 300 | - | -51 |
| Other assets and liabilities | 5,115 | -21,782 | 3,740 | 535 |
| Net cash provided by operating activities | 13,513 | 20,847 | 2,170 | 70,011 |
| Purchases of property, plant and equipment | 7,403 | 6,192 | 7,860 | 25,997 |
| Purchases of marketable securities | 220,143 | 108,692 | 138,419 | 312,990 |
| Sales and maturities of marketable securities | 123,814 | 142,656 | 146,925 | 242,527 |
| Acquisition of uk biocentre, net of cash acquired | 11,017 | - | 0 | - |
| Proceeds from other investment | 0 | - | 0 | 2,130 |
| Net investment hedge settlement | 0 | - | 180 | 3,043 |
| Deposit received for the sale of b medical systems business | 0 | 9,000 | - | - |
| Net cash used in investing activities | -114,749 | 36,772 | 826 | -91,287 |
| Proceeds from issuance of common stock | 1,179 | - | 1,217 | 1,553 |
| Share repurchases | - | - | 0 | 0 |
| Payments of finance leases | 197 | 214 | 400 | 585 |
| Withholding tax payments on net share settlements on equity awards | 2 | 2,418 | 0 | - |
| Excise tax payment for settled share repurchases | 0 | 0 | 0 | 11,376 |
| Net cash used in financing activities | 980 | -2,632 | 817 | -10,408 |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | -2,442 | 314 | -944 | 4,510 |
| Net decrease in cash, cash equivalents and restricted cash | -102,698 | 55,301 | 2,869 | -27,174 |
| Cash, cash equivalents and restricted cash, beginning of period | 351,986 | 296,685 | 320,990 | - |
| Cash, cash equivalents and restricted cash, end of period | 249,288 | 351,986 | 296,685 | - |
Azenta, Inc. (AZTA)
Azenta, Inc. (AZTA)